AURKB and cancer: Long et al (26) demonstrated that ZM447439, an inhibitor of Aurora-B, was significantly associated with a decrease in Akt phosphorylation (at Ser473) and a decrease in the phosphorylation of its substrates, glycogen synthase kinase 3-α and -β (at Ser21 and Ser9) in Hep2 cancer cells.